Fangman Chen
Impact in
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 2%
- Nanoplatforms for cancer theranostics
Papers in
-
- Nanoplatforms for cancer theranostics 35
- Biomaterials 18
- Nanoparticle-Based Drug Delivery 18
- Co-authors
- Dan Shao (59 shared papers)Wen‐Fei Dong (17 shared papers)Chao Yang (25 shared papers)Fan Zhang (13 shared papers)Zheng Wang (13 shared papers)Zhimin Chang (16 shared papers)Kam W. Leong (15 shared papers)Hanze Hu (9 shared papers)
- Journals
- Biomaterials (10 papers)Advanced Materials (8 papers)ACS Nano (4 papers)Advanced Science (4 papers)Frontiers in Bioengineering and Biotechnology (3 papers)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Fangman Chen
84 papers receiving 2.7k citations
Fangman Chen's Hit Papers
Peers
Comparison fields: 5 of 102
- Biomaterials 661
- Biomedical Engineering 841
- Pharmaceutical Science 124
- Molecular Medicine 96
- Immunology 270
Countries citing papers authored by Fangman Chen
This map shows the geographic impact of Fangman Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangman Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangman Chen more than expected).
Fields of papers citing papers by Fangman Chen
This network shows the impact of papers produced by Fangman Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangman Chen. The network helps show where Fangman Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Fangman Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 224 | |
| 2 | 2020 | 220 | |
| 3 | A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease Hit paper breakdown → | 2022 | 199 |
| 4 | 2022 | 177 | |
| 5 | Probiotic‐Inspired Nanomedicine Restores Intestinal Homeostasis in Colitis by Regulating Redox Balance, Immune Responses, and the Gut Microbiome Hit paper breakdown → | 2022 | 152 |
| 6 | 2022 | 128 | |
| 7 | 2019 | 82 | |
| 8 | 2021 | 82 | |
| 9 | 2023 | 67 | |
| 10 | 2024 | 64 | |
| 11 | 2015 | 57 | |
| 12 | 2022 | 53 | |
| 13 | 2022 | 52 | |
| 14 | 2021 | 47 | |
| 15 | 2021 | 45 | |
| 16 | 2020 | 44 | |
| 17 | 2022 | 43 | |
| 18 | 2023 | 43 | |
| 19 | 2018 | 42 | |
| 20 | 2017 | 41 |
About Fangman Chen
Fangman Chen is a scholar working on Biomedical Engineering, Biomaterials, Immunology, Rehabilitation and Materials Chemistry, having authored 88 papers that have together received 2.7k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (35 papers), Nanoparticle-Based Drug Delivery (18 papers), Immunotherapy and Immune Responses (7 papers), Wound Healing and Treatments (4 papers), Inflammatory Bowel Disease (4 papers), Tissue Engineering and Regenerative Medicine (3 papers), Carbon and Quantum Dots Applications (3 papers) and Heavy metals in environment (3 papers). The work is most often cited by research in Biomaterials (661 citations), Biomedical Engineering (841 citations), Pharmaceutical Science (124 citations), Molecular Medicine (96 citations) and Immunology (270 citations). Fangman Chen has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Dan Shao, Wen‐Fei Dong, Chao Yang, Fan Zhang, Zheng Wang, Zhimin Chang, Kam W. Leong, Hanze Hu, Wen Ce Sun and Xiao Zheng. Their work appears in journals such as Biomaterials, Advanced Materials, ACS Nano, Advanced Science and Frontiers in Bioengineering and Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.